Slide 1: Investor presentation – Broker Meets Biotech
For personal use only Investor presentation Broker Meets Biotech September 2017 1
Slide 2: Disclaimer
Disclaimer For personal use only Some of the information in this presentation may refer to Dimerix Limited (“Dimerix” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all
Slide 3: Investment highlights
Investment highlights Dimerix Limited (ASX:DXB) For personal use only 1. Using proprietary “Receptor HIT” drug discovery platform to identify multiple development programs 2. Lead program is DMX-200 in Phase 2 human trials for Chronic Kidney Disease • Using compounds that are already known 3. Positi
Slide 4: Corporate overview
Corporate overview For personal use only Corporate Snapshot Share price history ASX Code: DXB 0.02 Share Price (01 Sep 17): $.010 Market cap: $18.3m Cash (30 Jun 2017): $2.2m 0.01 (R&D Tax incentive approx $540K during 2017) Shares on issue*: 1,829.9m 0.00 Major Shareholders Mr Peter Meurs 17.33 Yod
Slide 5: Corporate history
Corporate history For personal use only 2004 - 2014 2015 - 2017 2004 2004 - 2014 2015 2016 2017 - Kathy Harrison - Head of Drug - Dimerix - Pre-clinical and proof of - Listed on ASX Development appointed CEO spun out of concept laboratory work appointed UWA - First patient - Positive FDA - March 201
Slide 6: Experienced board and management
Experienced board and management For personal use only Dr James Williams – Chairman Hugh Alsop – Director • Co-founder of Dimerix and iCeutica • Accomplished and commercially-focused (acquired in 2011 and now with 3 FDA pharmaceutical and biotechnology executive drug approvals) • Responsible for suc
Slide 7: Chronic kidney disease (CKD) - market opportunity
Chronic kidney disease (CKD) - market opportunity For personal use only • CKD is a global health problem affecting over 10% of the population with 26 million patients in the US alone • Growing in incidence due to large number of people living with obesity and diabetes • CKD gets progressively worse,
Slide 8: Current treatments for CKD
Current treatments for CKD For personal use only • Damaged kidneys “leak” proteins into the urine. This is called proteinuria and is the most common symptom of kidney disease – relevant measure of treatment efficacy (a prognostic indicator of future kidney damage). • First line therapy is reducing b
Slide 9: DMX-200 – Dimerix lead program for CKD
DMX-200 – Dimerix lead program for CKD For personal use only • DMX-200 is a tablet which is taken in conjunction with existing medications. • DMX-200 is being developed as an ‘adjunct’ therapy, avoiding complications of combination therapy development. • Patients continue taking their standard of ca
Slide 10: DMX-200 phase 2a trial outcomes
DMX-200 phase 2a trial outcomes For personal use only DMX-200 Trial • Primary end point met – no serious safety or 100% tolerability concerns observed when DMX-200 used Irbesartan: 24 – 38% reduction* (current standard of care) as an adjunct to standard of care drug, irbesartan“ DMX-200: further 50%
Slide 11: Next steps and newsflow
Next steps and newsflow For personal use only • Human pharmacokinetics study with extended release formulation on track to complete 2H CY2017. • Detailed Phase 2a data to be released on 2nd November 2017 in the Annual meeting of the American Society of Nephrology (ASN). • Phase 2b – to explore effic
Slide 12: Investment highlights
Investment highlights Dimerix Limited (ASX:DXB) For personal use only 1. Using proprietary “Receptor HIT” drug discovery platform to identify multiple development programs 2. Lead program is DMX-200 in Phase 2 human trials for Chronic Kidney Disease • Using compounds that are already known 3. Positi
Slide 13: Contact
For personal use only Contact Kathy Harrison Chief Executive Officer +61 419 359 149 kathy.harrison@dimerix.com Dimerix Limited ACN 001 285 230 www.dimerix.com